Lactoferrin and lysozyme in carcinomas of the parotid gland

Caselitz, J.; Jaup, T.; Seifert, G.

doi:10.1007/bf00431665

Cited by 63 publications

(12 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, LF was more often observed in low-grade ductal carcinomas with positive estrogen/progesterone receptors, confirming a decrease in LF immunostaining in less differentiated and more aggressive breast carcinomas (27–29). Therefore, LF may be a potential marker for glandular or acinar differentiation, similar to that previously observed in other malignancies (28,30,31). No data concerning LF immunodistribution in primary and metastatic lung cancer are currently available in literature.…”

Section: Discussionsupporting

confidence: 78%

Immunoexpression of lactoferrin in bone metastases and corresponding primary carcinomas

et al. 2013

View full text Add to dashboard Cite

Although the immunohistochemical presence of lactoferrin (LF) in pathological neoplastic bone and cartilage samples has previously been studied, no data concerning the distribution of LF in bone metastases of cancers that have originated from different organs are available at present. Consequently, using a monoclonal antibody, we have investigated the immunohistochemical LF pattern in 50 formalin-fixed and paraffin-embedded samples of human bone metastases and their corresponding primary carcinoma tumours (breast, 8; prostate, 4; kidney, 4; lung, 3; colon-rectum, 2 and uterus, 4). Quantification of LF immunoreactivity was performed using an intensity distribution (ID) score. LF immuno staining with a variable ID score was encountered in 11/25 (44%) metastatic lesions. In particular, the LF immunoreactivity was identified with a percentage ranging from 50 to 75% of bone metastases due to prostatic, renal, uterine and colorectal carcinomas; the positivity decreased in breast carcinomas (37.5%) and was completely absent in lung cancers. No differences in the LF-ID score were observed between primary and metastatic neoplastic localisations. Additionally, no correlations were identified between LF immunoexpression and the other parameters tested, including the age and gender of patients. Regardless of the mechanism of action of LF in human malignant tumours, we identified LF immunohistochemical reproducibility at primary and metastatic sites. Therefore, we hypothesise that the presence of LF in native neoplastic carcinomatous clones is maintained in secondary bone metastatic deposits.

show abstract

Section: Discussionsupporting

confidence: 78%

Immunoexpression of lactoferrin in bone metastases and corresponding primary carcinomas

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Immunohistochemistry has been used to study the distribution of LF in normal human tissues, such as stomach, kidney, lung, pancreas, liver and bone marrow (34). LF immunoreactivity has been extensively investigated in human neoplastic conditions (38–50). LF inhibited carcinogenesis and metastasis of malignant tumors in mice (51) and in the human pancreatic cell line SPA (52).…”

Section: Discussionmentioning

confidence: 99%

Characterization of proteins secreted by pancreatic cancer cells with anticancer drug treatment in vitro

et al. 2012

View full text Add to dashboard Cite

Pancreatic cancer is one of the most lethal cancers, with an incidence equaling mortality. It is a heterogeneous group of neoplasms in which pancreatic ductal adenocarcinoma is most common. Pancreatic cancer cannot be cured even if detected early. When treatment is initiated, a suitable method of administration of anticancer drugs must be chosen. Anticancer drugs kill tumor cells. However, side effects including initiation are problematic in anticancer drug therapy. Improved methods for the diagnosis of side effects of pancreatic cancer by using sensitive and specific tumor markers are highly desirable. Therefore, efficient strategies for biomarker discovery are urgently needed. Here, we present an approach based on direct experimental access to proteins released by PANC-1 human pancreatic cancer cells in vitro. A two-dimensional (2-D) map and catalog of this subproteome, herein termed the secretome, were established comprising more than 1,000 proteins observed by ‘2-D difference in-gel electrophoresis analysis using cyanine dye’. We investigated 22 spots that were 1.20-fold upregulated and 31 spots that were 0.66-fold downregulated by gemcitabine chloride treatment. Proteins in these spots were identified by nano-high-performance liquid chromatography electrospray ionization time of flight mass spectrometry/mass spectrometry. Most secretome constituents were nominally cellular proteins. By mass spectrometry screening, 14-3-3 protein sigma (14-3-3 σ), protein S100-A8, protein S100-A9, galectin-7, lactotransferrin (lactoferrin, LF) precursor, serotransferrin (transferrin) precursor, and vitamin D binding protein precursor were identified. Western blotting confirmed the presence of 14-3-3 σ and LF. We found that upregulation of 14-3-3 σ was associated with apoptosis, and downregulation of LF was found to suppress tumorigenesis.

show abstract

“…Recently, lactoferrin has been demonstrated by immunohistochemistry in adenocarcinomas of the parotid gland (Caselitz, Jaup & Seifert 1981, Seifert 1985, in welldifferentiated prostatic carcinomas (Barresi & Tuccari 1984) and in thyroid carcinomas (Tuccari & Barresi 1985a); in such neoplastic conditions lactoferrin has been regarded as a feature of 'glandular or follicular' differentiation (Caselitz et al 1981, Barresi & Tuccari 1984, Merlino et al 1985, Seifert 1985, Tuccari & Barresi 1985a.…”

Section: Introductionmentioning

confidence: 99%

Immunohistochemical demonstration of ceruloplasmin in follicular adenomas and thyroid carcinomas

Tuccari

Barresi

1987

Histopathology

View full text Add to dashboard Cite

The presence of ceruloplasmin in follicular adenomas (15 cases) and thyroid carcinomas (39) and two Hürthle cell tumours was investigated by immunohistochemical methods. Follicular adenomas were all negative whereas Hürthle cell tumours, follicular and papillary carcinomas exhibited various degrees of cytoplasmic positivity for ceruloplasmin. Highly atypical multinucleated cells and incorporated follicular structures observed in anaplastic carcinomas were positively stained; the spindle cell variety of these cancers was always negative for ceruloplasmin. Medullary carcinomas and normal thyroid tissue were constantly unstained. The distribution pattern of ceruloplasmin is the same as that of lactoferrin, a marker recently proposed for the differential diagnosis between follicular adenomas and thyroid carcinomas; these two glycoproteins are structurally related.

show abstract

Lactoferrin and lysozyme in carcinomas of the parotid gland

Cited by 63 publications

References 21 publications

Immunoexpression of lactoferrin in bone metastases and corresponding primary carcinomas

Immunoexpression of lactoferrin in bone metastases and corresponding primary carcinomas

Characterization of proteins secreted by pancreatic cancer cells with anticancer drug treatment in vitro

Immunohistochemical demonstration of ceruloplasmin in follicular adenomas and thyroid carcinomas

Contact Info

Product

Resources

About